147 related articles for article (PubMed ID: 11757700)
1. 6. Report on workshop: EBMT workshop "High dose therapy in aggressive NHL".
Schmitz N
Ann Hematol; 2001; 80 Suppl 3():B24-5. PubMed ID: 11757700
[No Abstract] [Full Text] [Related]
2. Therapeutic strategies for aggressive lymphomas: the trials of the DSHNHL.
Schmits R; Glass B; Trümper L; Pfreundschuh M;
Ann Hematol; 2001; 80 Suppl 3():B77-83. PubMed ID: 11757714
[No Abstract] [Full Text] [Related]
3. Treatment strategies in elderly patients with aggressive histology lymphoma.
Kouroukis CT; Meyer RM
Ann Hematol; 2001; 80 Suppl 3():B86-8. PubMed ID: 11757717
[No Abstract] [Full Text] [Related]
4. 4. Report on workshop: UICC workshop "Therapy of NHL in early stages". Part 2: Aggressive lymphomas.
Schmits R; Trümper L
Ann Hematol; 2001; 80 Suppl 3():B16-9. PubMed ID: 11757698
[No Abstract] [Full Text] [Related]
5. Indications for early autologous stem cell transplantation in aggressive lymphoma.
Kluin-Nelemans HC
Ann Hematol; 2001; 80 Suppl 3():B121-2. PubMed ID: 11757692
[No Abstract] [Full Text] [Related]
6. Aggressive lymphoma: improving treatment outcome with rituximab.
Coiffier B; Pfreundschuh M; Stahel R; Vose J; Zinzani PL
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S43-50. PubMed ID: 12710590
[TBL] [Abstract][Full Text] [Related]
7. [High-dose chemotherapy with bone marrow transplantation in recurrent or refractory NHL].
Torello E; Koziner B
Sangre (Barc); 1993 Dec; 38(6):473-80. PubMed ID: 7909622
[No Abstract] [Full Text] [Related]
8. Dose intensity or monoclonal antibody in first-line treatment.
Coiffier B
Hematol J; 2004; 5 Suppl 3():S154-8. PubMed ID: 15190299
[No Abstract] [Full Text] [Related]
9. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma.
Ladetto M; Zallio F; Vallet S; Ricca I; Cuttica A; Caracciolo D; Corradini P; Astolfi M; Sametti S; Volpato F; Bondesan P; Vitolo U; Boccadoro M; Pileri A; Gianni AM; Tarella C
Leukemia; 2001 Dec; 15(12):1941-9. PubMed ID: 11753616
[TBL] [Abstract][Full Text] [Related]
10. Investigation of monoclonal antibody therapy with conventional and high-dose treatment: current clinical trials.
Horning JS
Semin Hematol; 2000 Oct; 37(4 Suppl 7):27-33. PubMed ID: 11147487
[TBL] [Abstract][Full Text] [Related]
11. Non-Hodgkin lymphoma: an update.
Hennessy BT; Hanrahan EO; Daly PA
Lancet Oncol; 2004 Jun; 5(6):341-53. PubMed ID: 15172354
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies in lymphoid neoplasia: principles for optimal combined therapy.
Maloney GD
Semin Hematol; 2000 Oct; 37(4 Suppl 7):17-26. PubMed ID: 11147485
[TBL] [Abstract][Full Text] [Related]
13. High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: long-term analysis and future developments.
Tarella C; Cuttica A; Caracciolo D; Zallio F; Ricca I; Bergui L; Gavarotti P; Marinone C; Pagano M; Rossi G; de Crescenzo A; Salomone A; Ladetto M; Boccadoro M; Pileri A
Ann Hematol; 2001; 80 Suppl 3():B123-6. PubMed ID: 11757693
[No Abstract] [Full Text] [Related]
14. Innovative strategies in lymphoma therapy.
Jäger U
Wien Klin Wochenschr; 2003 Aug; 115(13-14):462-70. PubMed ID: 13677264
[TBL] [Abstract][Full Text] [Related]
15. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
Coiffier B
Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in indolent lymphomas.
Sousou T; Friedberg J
Semin Hematol; 2010 Apr; 47(2):133-42. PubMed ID: 20350660
[TBL] [Abstract][Full Text] [Related]
17. Rituxan immunotherapy and zevalin radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
White CA
Curr Pharm Biotechnol; 2003 Aug; 4(4):221-38. PubMed ID: 14529425
[TBL] [Abstract][Full Text] [Related]
18. Rituximab and dose dense chemotherapy in primary breast lymphoma.
Avilés A; Castañeda C; Neri N; Cleto S; Nambo MJ
Haematologica; 2007 Aug; 92(8):1147-8. PubMed ID: 17650450
[TBL] [Abstract][Full Text] [Related]
19. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation.
Tsai D; Moore H; Hardy C; Porter D; Loh E; Vaughn D; Luger S; Schuster S; Stadtmauer E
Bone Marrow Transplant; 1999 Sep; 24(5):521-6. PubMed ID: 10482937
[TBL] [Abstract][Full Text] [Related]
20. Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma.
Micallef IN; Kirk A; Norton A; Foran JM; Rohatiner AZ; Lister TA
Blood; 1999 Apr; 93(7):2427-8. PubMed ID: 10215354
[No Abstract] [Full Text] [Related]
[Next] [New Search]
